β-catenin Inhibitors in Cancer Therapeutics: Intricacies and Way Forward

Overview

Journal Bioengineered

Date 2023 Sep 1

PMID 37655825

Authors

Arundhathi Dev Jr

Meenakshi Vachher

Chandra Prakash Prasad

Affiliations

Soon will be listed here.

Abstract

β-catenin is an evolutionary conserved, quintessential, multifaceted protein that plays vital roles in cellular homeostasis, embryonic development, organogenesis, stem cell maintenance, cell proliferation, migration, differentiation, apoptosis, and pathogenesis of various human diseases including cancer. β-catenin manifests both signaling and adhesive features. It acts as a pivotal player in intracellular signaling as a component of versatile WNT signaling cascade involved in embryonic development, homeostasis as well as in carcinogenesis. It is also involved in Ca dependent cell adhesion via interaction with E-cadherin at the adherens junctions. Aberrant β-catenin expression and its nuclear accumulation promote the transcription of various oncogenes including c-Myc and cyclinD1, thereby contributing to tumor initiation, development, and progression. β-catenin's expression is closely regulated at various levels including its stability, sub-cellular localization, as well as transcriptional activity. Understanding the molecular mechanisms of regulation of β-catenin and its atypical expression will provide researchers not only the novel insights into the pathogenesis and progression of cancer but also will help in deciphering new therapeutic avenues. In the present review, we have summarized the dual functions of β-catenin, its role in signaling, associated mutations as well as its role in carcinogenesis and tumor progression of various cancers. Additionally, we have discussed the challenges associated with targeting β-catenin molecule with the presently available drugs and suggested the possible way forward in designing new therapeutic alternatives against this oncogene.

Citing Articles

PMEPA1 Binds NEDD4L to Inhibit the Malignant Progression of Multiple Myeloma by Inactivating Wnt/β-Catenin Signaling.

Hu S, Gao X, Zhu Y, Shi F, Huang L Cell Biochem Biophys. 2025; .

PMID: 40035958 DOI: 10.1007/s12013-025-01674-w.

AURKC Promotes Clear Cell Renal Cell Carcinoma Proliferation Through Upregulation of ERp57.

Liu Y, Wen Y, Nie Z, Jia L J Cancer. 2025; 16(4):1215-1227.

PMID: 39895780 PMC: 11786039. DOI: 10.7150/jca.103134.

CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.

Hirsch R, Premsankar S, Kurnit K, Chiou L, Rabjohns E, Lee H bioRxiv. 2024; .

PMID: 39605508 PMC: 11601622. DOI: 10.1101/2024.11.18.624183.

TOP2A Promotes Proliferation, Migration, and Inflammatory Response in M5-Treated Keratinocytes by Binding CTBP1 to Activate Wnt/β-Catenin Signaling.

Yang Y, Liu S, Xiao X Cell Biochem Biophys. 2024; .

PMID: 39565516 DOI: 10.1007/s12013-024-01620-2.

WNT7B promotes cancer progression via WNT/β-catenin signaling pathway and predicts a poor prognosis in oral squamous cell carcinoma.

Li Y, Huang L, Hu Q, Zheng K, Yan Y, Lan T BMC Oral Health. 2024; 24(1):1335.

PMID: 39487430 PMC: 11529306. DOI: 10.1186/s12903-024-05113-9.

References

Bienz M . beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol. 2005; 15(2):R64-7. DOI: 10.1016/j.cub.2004.12.058. View

Dominguez-Brauer C, Khatun R, Elia A, Thu K, Ramachandran P, Baniasadi S . E3 ubiquitin ligase Mule targets β-catenin under conditions of hyperactive Wnt signaling. Proc Natl Acad Sci U S A. 2017; 114(7):E1148-E1157. PMC: 5320996. DOI: 10.1073/pnas.1621355114. View

Guo W, Wisniewski J, Ji H . Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett. 2014; 24(11):2546-54. DOI: 10.1016/j.bmcl.2014.03.095. View

Gonsalves F, Klein K, Carson B, Katz S, Ekas L, Evans S . An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011; 108(15):5954-63. PMC: 3076864. DOI: 10.1073/pnas.1017496108. View

Neiheisel A, Kaur M, Ma N, Havard P, Shenoy A . Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Int J Cancer. 2021; 150(5):727-740. DOI: 10.1002/ijc.33811. View

Sadot E, Geiger B, Oren M, Ben-Zeev A . Down-regulation of beta-catenin by activated p53. Mol Cell Biol. 2001; 21(20):6768-81. PMC: 99855. DOI: 10.1128/MCB.21.20.6768-6781.2001. View

McCoy M, Spicer D, Wells N, Hoogewijs K, Fiedler M, Baud M . Biophysical Survey of Small-Molecule β-Catenin Inhibitors: A Cautionary Tale. J Med Chem. 2022; 65(10):7246-7261. PMC: 9150122. DOI: 10.1021/acs.jmedchem.2c00228. View

Lepourcelet M, Chen Y, France D, Wang H, Crews P, Petersen F . Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1):91-102. DOI: 10.1016/s1535-6108(03)00334-9. View

Jamieson C, Sharma M, Henderson B . Targeting the β-catenin nuclear transport pathway in cancer. Semin Cancer Biol. 2014; 27:20-9. DOI: 10.1016/j.semcancer.2014.04.012. View

10.

Borges K, Pignatti E, Leng S, Kariyawasam D, Ruiz-Babot G, Ramalho F . Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. Oncogene. 2020; 39(30):5282-5291. PMC: 7378041. DOI: 10.1038/s41388-020-1358-5. View

11.

Shang S, Hua F, Hu Z . The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017; 8(20):33972-33989. PMC: 5464927. DOI: 10.18632/oncotarget.15687. View

12.

van Kappel E, Maurice M . Molecular regulation and pharmacological targeting of the β-catenin destruction complex. Br J Pharmacol. 2017; 174(24):4575-4588. PMC: 5727331. DOI: 10.1111/bph.13922. View

13.

Greenblatt M, Shin D, Oh H, Lee K, Zhai B, Gygi S . MEKK2 mediates an alternative β-catenin pathway that promotes bone formation. Proc Natl Acad Sci U S A. 2016; 113(9):E1226-35. PMC: 4780654. DOI: 10.1073/pnas.1600813113. View

14.

Prasad C, Chaurasiya S, Axelsson L, Andersson T . WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol Oncol. 2013; 7(5):870-83. PMC: 5528454. DOI: 10.1016/j.molonc.2013.04.005. View

15.

Lai K, Nguyen C, Lee K, Lee A, Lin D, Teo J . Convergence of Canonical and Non-Canonical Wnt Signal: Differential Kat3 Coactivator Usage. Curr Mol Pharmacol. 2019; 12(3):167-183. PMC: 6687580. DOI: 10.2174/1874467212666190304121131. View

16.

Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

17.

Sato A, Shimizu M, Goto T, Masuno H, Kagechika H, Tanaka N . WNK regulates Wnt signalling and β-Catenin levels by interfering with the interaction between β-Catenin and GID. Commun Biol. 2020; 3(1):666. PMC: 7665214. DOI: 10.1038/s42003-020-01386-2. View

18.

Kang Y, Park H, Chung H, Min H, Park E, Lee M . Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells. Mol Pharmacol. 2012; 82(2):168-77. DOI: 10.1124/mol.112.078535. View

19.

Kim G, Kurnit K, Djordjevic B, Singh C, Munsell M, Wang W . Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018; 31(10):1553-1559. PMC: 6168348. DOI: 10.1038/s41379-018-0080-0. View

20.

Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada J . Somatic mutations of the APC gene in primary breast cancers. Am J Pathol. 2000; 156(6):1997-2005. PMC: 1850076. DOI: 10.1016/s0002-9440(10)65072-9. View